8-K: Regen Biopharma Declares Preferred Stock Dividend

Regen Biopharma, Inc. announced a dividend payable in Series A Preferred Stock to shareholders of record as of February 3, 2026.

Summary

• Regen Biopharma, Inc.'s Board of Directors declared a dividend on January 19, 2026.
• The dividend is payable in shares of the company's authorized but unissued Series A Preferred Stock.
• Shareholders of record as of February 3, 2026 (Record Date) will receive the dividend.
• The dividend will be paid on or about February 9, 2026.
• The distribution ratio is one share of Series A Preferred Stock for every one share of Regen Biopharma, Inc. Common Stock, Series A Preferred Stock, Series AA Preferred Stock, Series M Preferred Stock, and Series NC Preferred Stock owned as of the Record Date.

Sentiment

Score: 7

Explanation: The declaration of a stock dividend is generally positive for existing shareholders as it provides additional equity, though it does not involve a cash payout and does not fundamentally alter the company's valuation.

Positives

• The declaration of a dividend provides additional shares to existing shareholders, indicating a return of value.
• It demonstrates the Board's decision to distribute value to its equity holders.

Future Outlook

The company expects to pay the declared dividend on or about February 9, 2026.

Industry Context

This announcement is a specific corporate action by Regen Biopharma, Inc. and does not directly reflect broader industry trends or competitive dynamics within the biopharma sector based on the information provided.

Stakeholder Impact

• Shareholders will receive additional shares of Series A Preferred Stock, increasing their equity holdings in the company.

Next Steps

• Payment of the Series A Preferred Stock dividend to eligible shareholders on or about February 9, 2026.

Key Dates

Recommendation

The declaration of a stock dividend in Series A Preferred Stock provides additional shares to existing holders, which is generally a positive signal of returning value. However, it does not involve a cash payout and does not fundamentally alter the company's underlying value or financial position, thus a 'hold' recommendation is appropriate for existing investors.

Keywords

Regen Biopharma, dividend, Series A Preferred Stock, stock dividend, corporate action, shareholder value